Adicet Bio Inc (ACET)

Dec 21, 2024

Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World

Dec 21, 2024

Dec 20, 2024

Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - Yahoo! Voices

Dec 20, 2024

Dec 20, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World

Dec 20, 2024

Dec 19, 2024

Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks

Dec 19, 2024

Dec 19, 2024

Adicet Bio's (ACET) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 19, 2024

Dec 19, 2024

Adicet Bio begins trial for kidney cancer therapy - Investing.com

Dec 19, 2024

Dec 19, 2024

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - BioSpace

Dec 19, 2024

Dec 19, 2024

ACET stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa

Dec 19, 2024

Dec 19, 2024

ACET stock touches 52-week low at $0.89 amid market challenges - Investing.com Canada

Dec 19, 2024

Dec 18, 2024

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - BioSpace

Dec 18, 2024

Dec 18, 2024

Adicet Bio Names Dr. Julia Maltzman As Chief Medical Officer - Contract Pharma

Dec 18, 2024

Dec 18, 2024

Adicet Bio names new Chief Medical Officer - Investing.com

Dec 18, 2024

Dec 16, 2024

Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com

Dec 16, 2024

Dec 14, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - MarketBeat

Dec 14, 2024

Dec 14, 2024

Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 18.1% - Defense World

Dec 14, 2024

Dec 04, 2024

Adicet Bio's SWOT analysis: gamma-delta T cell stock faces CAR-T challenges - Investing.com

Dec 04, 2024

Dec 03, 2024

Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Rises By 6.1% - MarketBeat

Dec 03, 2024

Nov 29, 2024

Adicet Bio Awards New Employee Stock Options at $1.13 Per Share in Inducement Grant | ACET Stock News - StockTitan

Nov 29, 2024

Nov 28, 2024

Adicet Bio clears debt with Banc of California By Investing.com - Investing.com South Africa

Nov 28, 2024

Nov 28, 2024

Adicet Bio clears debt with Banc of California - Investing.com India

Nov 28, 2024

Nov 27, 2024

Adicet Bio Clears Debts with Banc of California - TipRanks

Nov 27, 2024

Nov 26, 2024

Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register

Nov 26, 2024

Nov 26, 2024

GSA Capital Partners LLP Has $56,000 Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World

Nov 26, 2024

Nov 22, 2024

Adicet Bio, Inc. Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Marketscreener.com

Nov 22, 2024

Nov 20, 2024

Adicet Bio Reports Q3 2024 Results and Clinical Progress - TipRanks

Nov 20, 2024

Nov 20, 2024

Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World

Nov 20, 2024

Nov 19, 2024

First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease - CGTLive™

Nov 19, 2024

Nov 19, 2024

Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET - Nasdaq

Nov 19, 2024

Nov 19, 2024

Adicet Bio begins trial for innovative cancer therapy By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Adicet Bio Advances Cancer and Autoimmune Trials - TipRanks

Nov 18, 2024

Nov 18, 2024

Adicet Bio begins trial for innovative cancer therapy - Investing.com

Nov 18, 2024

Nov 18, 2024

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire

Nov 18, 2024

Nov 18, 2024

Adicet Bio begins lupus nephritis trial, eyes other diseases By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Adicet Bio's (ACET) Neutral Rating Reiterated at HC Wainwright - MarketBeat

Nov 18, 2024

Nov 18, 2024

Adicet Bio begins lupus nephritis trial, eyes other diseases - Investing.com

Nov 18, 2024

Nov 18, 2024

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire

Nov 18, 2024

Nov 18, 2024

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Nov 18, 2024

Nov 18, 2024

Adicet Bio Launches Phase 1 Trial for Lupus Drug with FDA Fast Track Status - StockTitan

Nov 18, 2024

Nov 16, 2024

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire

Nov 16, 2024

Nov 16, 2024

Adicet Bio's ADI-001 Shows Breakthrough CAR T Cell Results in Autoimmune Treatment Study - StockTitan

Nov 16, 2024

Nov 16, 2024

Adicet Bio amends loan terms with PacWest Bank By Investing.com - Investing.com Nigeria

Nov 16, 2024

Nov 15, 2024

RA Capital Management, L.P. Expands Stake in Adicet Bio Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

ACET stock touches 52-week low at $1.04 amid market challenges - Investing.com

Nov 14, 2024

Nov 12, 2024

Adicet Bio To Present At Guggenheim Securities Healthcare Innovation Conference; Webcast At 3:00 PM - Nasdaq

Nov 12, 2024

Nov 11, 2024

FY2024 EPS Estimates for Adicet Bio Lowered by HC Wainwright - MarketBeat

Nov 11, 2024

Nov 11, 2024

HC Wainwright Decreases Earnings Estimates for Adicet Bio - Defense World

Nov 11, 2024

Nov 09, 2024

Wedbush Reiterates “Outperform” Rating for Adicet Bio (NASDAQ:ACET) - Defense World

Nov 09, 2024

Nov 07, 2024

Adicet Bio (NASDAQ:ACET) Announces Earnings Results, Hits Estimates - MarketBeat

Nov 07, 2024

Nov 06, 2024

Adicet Bio Expands Trial Portfolio, Secures FDA Fast Track Status Despite $30.5M Loss | ACET Stock News - StockTitan

Nov 06, 2024

Nov 05, 2024

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire

Nov 05, 2024

Nov 01, 2024

Adicet Bio to Participate in Upcoming Investor Conferences - Business Wire

Nov 01, 2024